Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, 10x Genomics, Inc. reported revenue of $643M, up 5.2% year over year. Operating margin was -9.5% and net margin -6.8%, on a free-cash-flow margin of 20.2% with capital expenditure at 0.9% of revenue. Every figure is computed directly from TXG's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $643M | -9.5% | -6.8% |
| FY2024 | $611M | -31.9% | -29.9% |
| FY2023 | $619M | -42.9% | -41.2% |
| FY2022 | $516M | -32.5% | -32.1% |
| FY2021 | $490M | -10.7% | -11.9% |
How does TXG compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.